MedPath
Found 6 clinical trials|View Analysis
Sort by:

Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers

Phase 1
Not yet recruiting
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
Drug: TQB2928 injection + Almonertinib Mesilate Tablets
First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Target Recruit Count
20
Registration Number
NCT06585059
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Phase 1
Recruiting
Conditions
Other Solid Tumors
Osteosarcoma
Interventions
Drug: 1800mg of TQB2928 injection+Anlotinib
Drug: 1200mg of TQB2928 injection+Anlotinib
First Posted Date
2024-06-03
Last Posted Date
2024-06-03
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Target Recruit Count
43
Registration Number
NCT06438783
Locations
🇨🇳

Beijing jishuitan hospital, Beijing, Beijing, China

🇨🇳

Pekjing university people's hospital, Beijing, Beijing, China

🇨🇳

Hunan cancer hospital, Changsha, Hunan, China

and more 2 locations

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

Phase 1
Terminated
Conditions
Advanced Malignant Neoplasm
Interventions
Drug: TQB2928 injection
Drug: Penpulimab
First Posted Date
2024-03-07
Last Posted Date
2024-08-06
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
3
Registration Number
NCT06297642
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China

🇨🇳

The Second People's Hospital of Hefei, Hefei, Anhui, China

🇨🇳

Lu'an People's Hospital of Anhui Province, Lu'an, Anhui, China

and more 2 locations

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Phase 1
Recruiting
Conditions
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Interventions
Drug: TQB2928 Injection + Azacitidine for injection
First Posted Date
2023-08-23
Last Posted Date
2023-09-06
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
48
Registration Number
NCT06008405
Locations
🇨🇳

Chongqing Hospital of Traditional Chinese Medicine, Chongqing, Chongqing, China

🇨🇳

The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

and more 6 locations

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers

Phase 1
Recruiting
Conditions
Advanced Cancer
Interventions
Drug: TQB2928 injection
First Posted Date
2022-01-14
Last Posted Date
2022-03-03
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Target Recruit Count
180
Registration Number
NCT05192512
Locations
🇨🇳

Sun Yat-sen University Cancer Cen, Guangzhou, Guangdong, China

🇨🇳

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers

Phase 1
Conditions
Advanced Solid Tumors and Hematological Malignancies
Interventions
Drug: TQB2928 Injection
First Posted Date
2021-04-22
Last Posted Date
2021-04-22
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
20
Registration Number
NCT04854681
© Copyright 2025. All Rights Reserved by MedPath